Talecris Biotherapeutics to Report First Quarter 2011 Financial Results

RESEARCH TRIANGLE PARK, N.C., April 14, 2011 /PRNewswire/ -- Talecris Biotherapeutics Holdings Corp. (NASDAQ: TLCR) will issue its first quarter earnings release after the market closes on April 27, 2011. Due to the pending merger with Grifols, S.A., Talecris will not be hosting a conference call to discuss its first quarter results.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit: www.talecris.com.

SOURCE Talecris Biotherapeutics, Inc.

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.